PRESENTATION OF THE STUDY SUPPORTED BY RAKFOND AT 2019 ASCO ANNUAL MEETING
Final results of the randomized phase II trial of olanzapine versus aprepitant in patients receiving high-emetogenic chemotherapy were presented by its author Dr. Alexey Rumyantsev at the Annual Meeting of the American Society of Clinical Oncology (ASCO) during the Symptoms and Survivorship session on June 3, 2019, in Chicago, USA. The study was carried out in the Department of Clinical Pharmacology and Chemotherapy of N.N. Blokhin National Medical Research Center of Oncology (Moscow, Russia). It was supported by the RUSSCO/RakFond’s Young Scientist & Early Career Investigator Oncology Research Grant.